비교리스트

 카트 문의
시장보고서
상품코드
1388185

특수 제네릭 의약품 시장 점유율, 규모, 동향, 산업 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2023-2032년)

Specialty Generics Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Injectables, Oral Drugs, Others); By Application; By End-use; By Region; Segment Forecast, 2023- 2032
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 115 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris market research의 최신 조사에 따르면, 세계 특수 제네릭 의약품 시장 규모는 2032년까지 9,480억 4,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

많은 제약사, 바이오 제약사, 의료기기 회사들은 다른 기업과의 합병이나 인수를 통해 시장에서의 입지를 확대하는 데 주력하고 있습니다. 암, 다발성 경화증(MS), HIV 등 생명을 위협하는 질병의 확산은 전 세계적으로 증가하고 있으며, 이는 특수 의약품에 대한 수요를 촉진할 것으로 예상됩니다. 특히 신흥국에서는 WHO의 6개 지역 중 5개 지역에서 만성질환이 주요 사망 원인으로 꼽히며 여전히 큰 우려를 낳고 있습니다. 사하라 사막 이남의 아프리카에서는 HIV와 같은 전염병이 여전히 만연해 있으며, 앞으로도 큰 문제가 될 것으로 예상됩니다. 예측 기간 동안 생명을 위협하는 질병의 높은 확산으로 인해 특수 의약품 시장은 급성장할 것으로 예상됩니다.

2020년, COVID-19는 의약품 시장에 큰 영향을 미쳐 일부 기업의 성장 둔화와 매출 감소를 초래했습니다. 제조 공장은 가동 중단에 직면했고, 임상시험과 연구를 중단해야 했고, 숙련공이 부족했습니다. 시장 세분화도 그러한 기업 중 하나이며, 주로 경쟁 심화와 전염병 기간 동안 시장 변화로 인한 제품 믹스의 변화로 인해 특수 제네릭 의약품 부문이 6.6% 감소했습니다. 그러나 2021년에는 집단 예방접종, 격리 규제 완화, 만성질환 치료를 위한 특수 의약품에 대한 수요 증가로 인해 시장이 회복될 조짐을 보이고 있습니다.

특수 제네릭 의약품 시장 보고서 하이라이트

예측 기간 동안 주사제 부문은 제약 산업에서 가장 크고 빠르게 성장하는 부문이 될 것으로 예상됩니다. 이는 주사제는 효과가 오래 지속되고 체내 흡수가 빠르기 때문에 환자의 순응도와 수용성이 높기 때문입니다. 신제품 승인이 증가하고 시장이 확대됨에 따라 이 부문은 빠르게 성장할 것으로 예상됩니다.

2022년 가장 큰 시장 점유율을 차지한 것은 염증성 질환 부문이었습니다. 류마티스 관절염과 같은 염증성 질환 환자 수는 전 세계적으로 증가하고 있습니다. 세계 RA 네트워크에 따르면 약 3,500억 명이 관절염을 앓고 있으며, 영국 NHS는 영국에서 100억 명 이상이 이 질환을 앓고 있다고 보고했습니다. 이러한 유병률 증가에 따라 헬스케어 업계의 주요 기업들은 이 분야에서 시장 점유율을 확대하고 있습니다.

2022년에는 전문 약국 부문이 가장 큰 시장 점유율을 차지했습니다. 대형 제네릭 의약품 제조업체와 보험사들은 유통 비용이 낮고 의약품을 쉽게 구할 수 있기 때문에 자사 제품의 유통을 전문 약국에 의존하는 경우가 많습니다.

미국 식품의약국(FDA)은 신제품 승인을 간소화하기 위한 규제 정책을 시행하고 있습니다. 국민들이 안전하고 효과적인 저가의 제네릭 의약품을 이용할 수 있도록 하기 위해 FDA는 해치-왁스만법에 근거한 제네릭 의약품 사용료 개정(GDUFA)을 비롯한 여러 가지 이니셔티브를 도입했습니다. 그 결과, 유명 제약사들은 지속적으로 특수 제네릭 의약품을 시장에 출시하기 위해 노력하고 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 특수 제네릭 의약품 시장에 관한 인사이트

  • 특수 제네릭 의약품 시장 - 최종 용도 현황
  • 특수 제네릭 의약품 시장 역학
    • 성장 촉진요인과 기회
      • 특수 제네릭 의약품 시장에서의 존재감을 확대하는 수단으로서 인수합병을 중시하는 추세 강화
      • 시장 성장을 촉진하는 특수 의약품 특허 기한 만료
    • 성장 억제요인과 과제
      • 수익성이 낮고, 이러한 의약품에 대한 인지도가 낮기 때문에 시장의 성장이 저해될 가능성
  • PESTEL 분석
  • 특수 제네릭 의약품 시장 최종 용도 동향
  • 밸류체인 분석
  • COVID-19 감염증의 영향 분석

제5장 세계의 특수 제네릭 의약품 시장, 유형별

  • 주요 조사 결과
  • 서론
  • 주사제
  • 경구제
  • 기타

제6장 세계의 특수 제네릭 의약품 시장, 용도별

  • 주요 조사 결과
  • 서론
  • 종양
  • 염증성 질환
  • 다발성 경화증
  • C형 간염
  • 기타

제7장 세계의 특수 제네릭 의약품 시장, 최종 용도별

  • 주요 조사 결과
  • 서론
  • 전문 약국
  • 소매 약국
  • 병원 약국

제8장 세계의 특수 제네릭 의약품 시장, 지역별

  • 주요 조사 결과
  • 서론
    • 특수 제네릭 의약품 시장 평가, 지역별, 2019-2032년
  • 특수 제네릭 의약품 시장 - 북미
    • 북미 : 특수 제네릭 의약품 시장, 유형별, 2019-2032년
    • 북미 : 특수 제네릭 의약품 시장, 최종 용도별, 2019-2032년
    • 북미 : 특수 제네릭 의약품 시장, 용도별, 2019-2032년
    • 특수 제네릭 의약품 시장 - 미국
    • 특수 제네릭 의약품 시장 - 캐나다
  • 특수 제네릭 의약품 시장 - 유럽
    • 유럽 : 특수 제네릭 의약품 시장, 유형별, 2019-2032년
    • 유럽 : 특수 제네릭 의약품 시장, 최종 용도별, 2019-2032년
    • 유럽 : 특수 제네릭 의약품 시장, 용도별, 2019-2032년
    • 특수 제네릭 의약품 시장 - 영국
    • 특수 제네릭 의약품 시장 - 프랑스
    • 특수 제네릭 의약품 시장 - 독일
    • 특수 제네릭 의약품 시장 - 이탈리아
    • 특수 제네릭 의약품 시장 - 스페인
    • 특수 제네릭 의약품 시장 - 네델란드
    • 특수 제네릭 의약품 시장 - 러시아
  • 특수 제네릭 의약품 시장 - 아시아태평양
    • 아시아태평양 : 특수 제네릭 의약품 시장, 유형별, 2019-2032년
    • 아시아태평양 : 특수 제네릭 의약품 시장, 최종 용도별, 2019-2032년
    • 아시아태평양 : 특수 제네릭 의약품 시장, 용도별, 2019-2032년
    • 특수 제네릭 의약품 시장 - 중국
    • 특수 제네릭 의약품 시장 - 인도
    • 특수 제네릭 의약품 시장 - 말레이시아
    • 특수 제네릭 의약품 시장 - 일본
    • 특수 제네릭 의약품 시장 - 인도네시아
    • 특수 제네릭 의약품 시장 - 한국
  • 특수 제네릭 의약품 시장 - 중동 및 아프리카
    • 중동 및 아프리카 : 특수 제네릭 의약품 시장, 유형별, 2019-2032년
    • 중동 및 아프리카 : 특수 제네릭 의약품 시장, 최종 용도별, 2019-2032년
    • 중동 및 아프리카 : 특수 제네릭 의약품 시장, 용도별, 2019-2032년
    • 특수 제네릭 의약품 시장 - 사우디아라비아
    • 특수 제네릭 의약품 시장 - UAE
    • 특수 제네릭 의약품 시장 - 이스라엘
    • 특수 제네릭 의약품 시장 - 남아프리카공화국
  • 특수 제네릭 의약품 시장 - 라틴아메리카
    • 라틴아메리카 : 특수 제네릭 의약품 시장, 유형별, 2019-2032년
    • 라틴아메리카 : 특수 제네릭 의약품 시장, 최종 용도별, 2019-2032년
    • 라틴아메리카 : 특수 제네릭 의약품 시장, 용도별, 2019-2032년
    • 특수 제네릭 의약품 시장 - 멕시코
    • 특수 제네릭 의약품 시장 - 브라질
    • 특수 제네릭 의약품 시장 - 아르헨티나

제9장 경쟁 상황

  • 확장과 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제10장 기업 개요

  • Apotex Corp.
  • Bausch Health Companies Inc.(Valeant Pharmaceuticals International, Inc.)
  • Dr. Reddy's Laboratories Ltd.
  • Endo Pharmaceuticals Inc.
  • Fresenius Kabi Brasil Ltda
  • Hikma Pharmaceuticals PLC
  • Mallinckrodt
  • Novartis AG(Sandoz International GmbH)
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceuticals Industries Ltd
  • Viatris Inc.
ksm 23.12.13

The global specialty generics drugs market size is expected to reach USD 948.04 billion by 2032, according to a new study by Polaris market research. The report "Specialty Generics Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Injectables, Oral Drugs, Others); By Application; By End-use; By Region; Segment Forecast, 2023- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Many pharmaceutical, biopharmaceutical, and medical device companies have been focusing on expanding their market presence by merging with or acquiring other companies. The prevalence of life-threatening diseases, such as cancer, Multiple Sclerosis (MS), and HIV, is increasing globally, which is expected to drive the demand for specialty medicines. Chronic diseases remain a major concern, particularly in emerging countries where they are the primary cause of mortality in five of the six WHO regions. Contagious diseases, such as HIV, are still widespread in Sub-Saharan Africa and are expected to continue to be a major issue. During the forecast period, the market for specialty medicines is expected to grow rapidly due to the high prevalence of life-threatening diseases.

In 2020, the COVID-19 pandemic had a significant impact on the pharmaceutical market, causing slower growth and a decline in net sales for several companies. Manufacturing plants had to face lockdown restrictions, clinical trials and studies had to be stopped, and there was a shortage of skilled labor. Mallinckrodt is one such company that experienced a -6.6% decline in its specialty generics segment, mainly due to increased competition and a change in product mix caused by market shifts during the pandemic. However, the market is showing signs of recovery in 2021, with mass vaccinations, easing of lockdown restrictions, and a growing demand for specialty medicines to treat chronic conditions.

Virtual trials offer numerous advantages, including remote data collection, increased participant engagement, and larger population inclusion. They minimize risks associated with in-person visits and reduce the burden on participants, coordinators, and investigators. By leveraging virtual methods, the clinical trials industry can overcome challenges, improve efficiency, and facilitate prompt and effective data collection.

Specialty generics drugs Market Report Highlights

During the forecast period, the Injectables segment is expected to be the largest and fastest-growing segment in the pharmaceutical industry. This is due to its ability to have long-lasting effects and quick absorption into the body, resulting in higher patient compliance and acceptance. With the increased approvals of new products and the expansion of the market, the segment is anticipated to grow rapidly.

In 2022, the largest market share was held by the segment of inflammatory conditions. The number of individuals with inflammatory conditions like rheumatoid arthritis is increasing globally. According to the Global RA Network, around 350 Billion people are living with arthritis, while the NHS has reported that over 10 Billion people in the UK are affected. In response to this rise in prevalence, major players in the healthcare industry are expanding their market share in this sector.

In 2022, the organic segment had the largest share. Organic bread improvers are made from organic ingredients and produced using organic farming methods. This means they are free from synthetic chemicals and GMOs. These organic improvers contain natural additives sourced from organic materials.

In 2022, the specialty pharmacy segment held the largest market share. Major generic manufacturers and insurance providers often rely on specialty pharmacies to distribute their products because of the low distribution costs and the easy accessibility of medicines offered by these pharmacies.

The US Food and Drug Administration (FDA) has implemented supportive regulatory policies to simplify the approval of new products. In order to make sure the public has access to safe and effective low-cost generic drugs, the agency has put several initiatives in place, including the Generic Drug User Fee Amendments (GDUFA) under the Hatch-Waxman Act. Consequently, prominent manufacturers are constantly working to introduce specialty generic drugs to the market.

The global key market players include: Apotex Corp., Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.), Dr. Reddy's Laboratories Ltd., Endo Pharmaceuticals Inc., Fresenius Kabi Brasil Ltda, Hikma Pharmaceuticals PLC, Mallinckrodt, Novartis AG (Sandoz International GmbH)

Polaris market research has segmented the Speciality generics drugs market report based on type, application, end-user, and region:

Specialty generics drugs, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Injectables
  • Oral Drugs
  • Others

Specialty generics drugs, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oncology
  • Inflamatory conditions
  • Multiple sclerosis
  • Hepatitis C
  • Others

Speciality generics drugs, End-Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Specialty pharmacy
  • Retail pharmacy
  • Hospital pharmacy

Speciality generics drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Specialty Generics Drugs Market Insights

  • 4.1. Specialty Generics Drugs Market - End-Use Snapshot
  • 4.2. Specialty Generics Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing emphasizing mergers and acquisitions as a means of expanding their presence in the specialty generics market
      • 4.2.1.2. The expiration of patents on specialty drugs to drive the market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Low profitability and lack of awareness about these drugs, hinder the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Specialty Generics Drugs Market End-Use Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Specialty Generics Drugs Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Injectables
    • 5.3.1. Global Specialty Generics Drugs Market, by Injectables, by Region, 2019-2032 (USD Billion)
  • 5.4. Oral Drugs
    • 5.4.1. Global Specialty Generics Drugs Market, by Oral Drugs, by Region, 2019-2032 (USD Billion)
  • 5.5. Others
    • 5.5.1. Global Specialty Generics Drugs Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Specialty Generics Drugs Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Oncology
    • 6.3.1. Global Specialty Generics Drugs Market, by Oncology, by Region, 2019-2032 (USD Billion)
  • 6.4. Inflamatory conditions
    • 6.4.1. Global Specialty Generics Drugs Market, by Inflamatory conditions, by Region, 2019-2032 (USD Billion)
  • 6.5. Multiple sclerosis
    • 6.5.1. Global Specialty Generics Drugs Market, by Multiple sclerosis, by Region, 2019-2032 (USD Billion)
  • 6.6. Hepatitis C
    • 6.6.1. Global Specialty Generics Drugs Market, by Hepatitis C, by Region, 2019-2032 (USD Billion)
  • 6.7. Others
    • 6.7.1. Global Specialty Generics Drugs Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Specialty Generics Drugs Market, by End-Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
  • 7.3. Specialty pharmacy
    • 7.3.1. Global Specialty Generics Drugs Market, by Specialty pharmacy, By Region, 2019-2032 (USD Billion)
  • 7.4. Retail pharmacy
    • 7.4.1. Global Specialty Generics Drugs Market, by Retail pharmacy, By Region, 2019-2032 (USD Billion)
  • 7.5. Hospital pharmacy
    • 7.5.1. Global Specialty Generics Drugs Market, by Hospital pharmacy, By Region, 2019-2032 (USD Billion)

8. Global Specialty Generics Drugs Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Specialty Generics Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Specialty Generics Drugs Market - North America
    • 8.3.1. North America: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
    • 8.3.3. North America: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.3.4. Specialty Generics Drugs Market - U.S.
      • 8.3.4.1. U.S.: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.3.5. Specialty Generics Drugs Market - Canada
      • 8.3.5.1. Canada: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.4. Specialty Generics Drugs Market - Europe
    • 8.4.1. Europe: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.4. Specialty Generics Drugs Market - UK
      • 8.4.4.1. UK: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.5. Specialty Generics Drugs Market - France
      • 8.4.5.1. France: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.6. Specialty Generics Drugs Market - Germany
      • 8.4.6.1. Germany: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.7. Specialty Generics Drugs Market - Italy
      • 8.4.7.1. Italy: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.8. Specialty Generics Drugs Market - Spain
      • 8.4.8.1. Spain: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.9. Specialty Generics Drugs Market - Netherlands
      • 8.4.9.1. Netherlands: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.10. Specialty Generics Drugs Market - Russia
      • 8.4.10.1. Russia: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.5. Specialty Generics Drugs Market - Asia Pacific
    • 8.5.1. Asia Pacific: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.4. Specialty Generics Drugs Market - China
      • 8.5.4.1. China: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.5. Specialty Generics Drugs Market - India
      • 8.5.5.1. India: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.6. Specialty Generics Drugs Market - Malaysia
      • 8.5.6.1. Malaysia: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.7. Specialty Generics Drugs Market - Japan
      • 8.5.7.1. Japan: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.8. Specialty Generics Drugs Market - Indonesia
      • 8.5.8.1. Indonesia: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.9. Specialty Generics Drugs Market - South Korea
      • 8.5.9.1. South Korea: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.6. Specialty Generics Drugs Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.4. Specialty Generics Drugs Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.5. Specialty Generics Drugs Market - UAE
      • 8.6.5.1. UAE: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.6. Specialty Generics Drugs Market - Israel
      • 8.6.6.1. Israel: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.7. Specialty Generics Drugs Market - South Africa
      • 8.6.7.1. South Africa: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.7. Specialty Generics Drugs Market - Latin America
    • 8.7.1. Latin America: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.7.4. Specialty Generics Drugs Market - Mexico
      • 8.7.4.1. Mexico: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.7.5. Specialty Generics Drugs Market - Brazil
      • 8.7.5.1. Brazil: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.7.6. Specialty Generics Drugs Market - Argentina
      • 8.7.6.1. Argentina: Specialty Generics Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Specialty Generics Drugs Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Specialty Generics Drugs Market, by Application, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Apotex Corp.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Dr. Reddy's Laboratories Ltd.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Endo Pharmaceuticals Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Fresenius Kabi Brasil Ltda
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Hikma Pharmaceuticals PLC
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Mallinckrodt
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Novartis AG (Sandoz International GmbH)
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. STADA Arzneimittel AG
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10.Sun Pharmaceutical Industries Ltd
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Teva Pharmaceuticals Industries Ltd
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Viatris Inc.
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제